Analyzing the options chain of IOVA Iovance Biotherapeutics prior to the earnings report this week,
I would consider purchasing the 7.5usd strike price Puts with
an expiration date of 2023-6-16,
for a premium of approximately $0.70
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Looking forward to read...
IOVA formed a large bearish Rising Wedge on this Weekly timeframe
This has led to a big downward move, which correlates well with the rising wedge, being a primarily bearish pattern
Support has yet to be found on the Weekly timeframe
Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient's own immune cells to attack cancer. TIL cells are extracted from a patient's own tumor tissue, expanded through a proprietary...
COMPLETE UPDATE FOR IOVA.
Notes: The difference between complete draft and incomplete draft is basically blind spots that show up on different looks. Anyway, under 35 is moderately strong buy for 43-44 late January or early February.
THE LIGHT GRAY ROUTE IS TECHNICALLY DRAFT 1 EVEN THOUGH I DIDN'T CALL IT THAT.
Notes: I started this for a request a while ago, but noticed that its strong bounce after the recent sell off (bad news from FDA or something like that) had real volume structure that is ahead of price. That is to say that this is a strong stock that may catch all sorts of fire after...
